L3VLUP
ProSign in

BSX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BSXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BSX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterBSXLLY
Q3 202031 holders, $15.0bn33 holders, $14.1bn
Q4 202035 holders, $13.6bn29 holders, $17.3bn
Q1 202129 holders, $15.7bn24 holders, $23.0bn
Q2 202127 holders, $18.2bn24 holders, $27.8bn
Q3 202127 holders, $18.2bn31 holders, $29.9bn
Q4 202126 holders, $17.4bn31 holders, $34.7bn
Q1 202232 holders, $17.4bn24 holders, $35.3bn
Q2 202230 holders, $14.0bn33 holders, $42.7bn
Q3 202229 holders, $14.5bn31 holders, $43.4bn
Q4 202226 holders, $16.6bn31 holders, $46.6bn
Q1 202332 holders, $18.5bn33 holders, $44.3bn
Q2 202337 holders, $19.6bn37 holders, $59.6bn
Q3 202333 holders, $19.7bn44 holders, $67.6bn
Q4 202330 holders, $20.6bn45 holders, $73.6bn
Q1 202433 holders, $24.0bn41 holders, $95.3bn
Q2 202435 holders, $26.8bn43 holders, $110bn
Q3 202440 holders, $28.3bn45 holders, $107bn
Q4 202440 holders, $29.4bn46 holders, $93.9bn
Q1 202544 holders, $33.1bn42 holders, $98.4bn
Q2 202544 holders, $33.6bn43 holders, $93.2bn
Q3 202548 holders, $29.5bn39 holders, $86.7bn
Q4 202549 holders, $28.5bn41 holders, $123bn
Q1 202645 holders, $17.2bn39 holders, $106bn
Q2 202640 holders, $13.0bn44 holders, $132bn
BSX

Boston Scientific Corp

Holders
30
Reported value
$20.6bn
Buyers
14
Sellers
19

Breadth -5 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
45
Reported value
$73.6bn
Buyers
27
Sellers
21

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 50 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BSX (5)

Eisler Capital Management Ltd, Farallon Capital Management LLC, Schonfeld Strategic Advisors LLC, Steadfast Capital Management LP, Walleye Capital LLC

Only LLY (20)

Acadian Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Coatue Management LLC, D. E. Shaw & Co., ExodusPoint Capital Management LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Man Group PLC, Moore Capital Management LP, Polen Capital Management LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Soros Fund Management LLC, Squarepoint Ops LLC, Susquehanna International Group LLP, Tiger Global Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →